Kavelaars X, Mulder J, Kaptein M
Multivariate Behav Res. 2024; 59(4):859-882.
PMID: 38733304
PMC: 11548885.
DOI: 10.1080/00273171.2024.2337340.
Kavelaars X, Mulder J, Kaptein M
BMC Med Res Methodol. 2023; 23(1):220.
PMID: 37798704
PMC: 10552398.
DOI: 10.1186/s12874-023-02034-z.
Wang P, Chow S
Orphanet J Rare Dis. 2023; 18(1):299.
PMID: 37740206
PMC: 10517458.
DOI: 10.1186/s13023-023-02909-w.
Meyer E, Mesenbrink P, Di Prospero N, Pericas J, Glimm E, Ratziu V
PLoS One. 2023; 18(3):e0281674.
PMID: 36893087
PMC: 9997886.
DOI: 10.1371/journal.pone.0281674.
Davis-Plourde K, Taljaard M, Li F
Stat Med. 2022; 42(4):559-578.
PMID: 36565050
PMC: 9985483.
DOI: 10.1002/sim.9632.
Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights.
Marsal J, Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D
Trials. 2022; 23(1):1037.
PMID: 36539800
PMC: 9769015.
DOI: 10.1186/s13063-022-06977-4.
Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
Bofill Roig M, Melis G, Posch M, Koenig F
Biostatistics. 2022; 25(1):237-252.
PMID: 36150142
PMC: 10939415.
DOI: 10.1093/biostatistics/kxac040.
Power analysis for cluster randomized trials with continuous coprimary endpoints.
Yang S, Moerbeek M, Taljaard M, Li F
Biometrics. 2022; 79(2):1293-1305.
PMID: 35531926
PMC: 11321238.
DOI: 10.1111/biom.13692.
Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints.
McMenamin M, Barrett J, Berglind A, Wason J
Stat Med. 2022; 41(13):2303-2316.
PMID: 35199380
PMC: 7612654.
DOI: 10.1002/sim.9356.
Sample size calculation in hierarchical factorial trials with unequal cluster sizes.
Tian Z, Esserman D, Tong G, Blaha O, Dziura J, Peduzzi P
Stat Med. 2022; 41(4):645-664.
PMID: 34978097
PMC: 8962918.
DOI: 10.1002/sim.9284.
A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches.
Montepiedra G, Ramchandani R, Miyahara S, Kim S
Stat Med. 2020; 40(2):327-348.
PMID: 33105524
PMC: 7770022.
DOI: 10.1002/sim.8777.
Decision-making with multiple correlated binary outcomes in clinical trials.
Kavelaars X, Mulder J, Kaptein M
Stat Methods Med Res. 2020; 29(11):3265-3277.
PMID: 32672498
PMC: 7682528.
DOI: 10.1177/0962280220922256.
Incorporating biomarkers to improve statistical power of immunotherapeutic neoadjuvant clinical trials in patients with triple-negative breast cancer.
Gao F, Wang G, Luo J, Liu J, Chen L, Xiong C
Stat Biopharm Res. 2019; 11(3):210-219.
PMID: 31467642
PMC: 6714581.
DOI: 10.1080/19466315.2018.1518259.
Bin-CE: A comprehensive web application to decide upon the best set of outcomes to be combined in a binary composite endpoint.
Marsal J, Ferreira-Gonzalez I, Ribera A, Oristrell G, Pijoan J, Garcia-Dorado D
PLoS One. 2018; 13(12):e0209000.
PMID: 30543676
PMC: 6292611.
DOI: 10.1371/journal.pone.0209000.
Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints.
Yang J, Li J, Wang S, Luo L, Liu P
Hum Vaccin Immunother. 2018; 15(1):256-263.
PMID: 30273507
PMC: 6363135.
DOI: 10.1080/21645515.2018.1514221.
Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
Hamasaki T, Evans S, Asakura K
J Biopharm Stat. 2017; 28(1):28-51.
PMID: 29083951
PMC: 6135538.
DOI: 10.1080/10543406.2017.1378668.
Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.
Ando Y, Hamasaki T, Evans S, Asakura K, Sugimoto T, Sozu T
Stat Biopharm Res. 2015; 7(2):81-94.
PMID: 26167243
PMC: 4497828.
DOI: 10.1080/19466315.2015.1006373.
Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.
Hamasaki T, Asakura K, Evans S, Sugimoto T, Sozu T
Stat Biopharm Res. 2015; 7(1):36-54.
PMID: 25844122
PMC: 4382106.
DOI: 10.1080/19466315.2014.1003090.
Registration and design alterations of clinical trials in critical care: a cross-sectional observational study.
Anand V, Scales D, Parshuram C, Kavanagh B
Intensive Care Med. 2014; 40(5):700-22.
PMID: 24737256
DOI: 10.1007/s00134-014-3250-7.
Sample size determination in group-sequential clinical trials with two co-primary endpoints.
Asakura K, Hamasaki T, Sugimoto T, Hayashi K, Evans S, Sozu T
Stat Med. 2014; 33(17):2897-913.
PMID: 24676799
PMC: 4082481.
DOI: 10.1002/sim.6154.